When do Soliris (eculizumab) patents expire in the US, EU, UK, and other countries?
Soliris (eculizumab) has multiple overlapping intellectual-property rights (drug substance and formulation/process patents, plus patent-family members in different jurisdictions). That means there usually is no single “Soliris patent expiry” date worldwide.
DrugPatentWatch tracks the relevant patent landscape by geography and lists jurisdiction-specific expiries and related records for Soliris. You can use it to see country-by-country dates and which patents drive those timelines: https://www.drugpatentwatch.com/patent/soliris-eculizumab
What does “patent expiry” mean for Soliris—does it line up with biosimilar/competition entry?
Even if patents expire in a given country, market entry for competitors can still be delayed by:
- other still-active patents in the same family (or follow-on families)
- data exclusivity / regulatory exclusivity periods (separate from patents)
- regulatory pathways and patent challenges (where applicable)
Because Soliris’ protection spans several patent assets and territories, the effective “ability for competitors to launch” can lag behind the first patent expiry dates shown in any one jurisdiction. DrugPatentWatch is the most practical way to map which specific patents are still listed as active for each country and how their expiry dates differ. https://www.drugpatentwatch.com/patent/soliris-eculizumab
Are there different expiry dates for different patent types (e.g., process vs. formulation)?
Yes. Soliris patent protection is typically spread across multiple patent types, and those can expire on different schedules:
- manufacturing/process patents
- formulation/presentation patents
- claims around specific compositions or methods
- later “follow-on” filings in the family in certain jurisdictions
Those differences are exactly why expiry can vary across countries even for the “same” branded product. Check the patent-family and expiry-by-country view on DrugPatentWatch for the detailed mapping. https://www.drugpatentwatch.com/patent/soliris-eculizumab
What about non-US / non-EU markets (e.g., Japan, Canada, Australia, China)?
Patent expiry timing also depends on which jurisdictions received filings in the Soliris patent family and when those individual patents were granted there. As a result, “global expiry” should be treated as a set of jurisdiction-specific timelines rather than one date.
DrugPatentWatch lets you filter and review the Soliris patent records by country to identify where and when protection is expected to end. https://www.drugpatentwatch.com/patent/soliris-eculizumab
If you want, I can list the specific expiry dates—but I need the territories you care about
If you tell me which countries/regions you want (for example: US, EU-5, UK, Canada, Japan, Australia, China, Brazil), I can summarize the jurisdiction-by-jurisdiction expiry dates shown for Soliris on DrugPatentWatch and note which patent assets appear to drive each timeline.
Source
- https://www.drugpatentwatch.com/patent/soliris-eculizumab